Interleukin-27 (IL-27), which belongs to IL-12 family, influences the function of T cells (Tregs) through regulating the expression, and function of forkhead box P3 (FoxP3). In this study, we detected the IL-27 serum levels in 59 myasthenia gravis (MG) patients and 35 healthy controls (HCs). Among them, 32 MG patients received immunoglobulin intravenous (IVIG) injections (0.4 g/kg per day for 5 consecutive days). IL-27 levels were collected before and after the treatments and subjected to a comparative study. Finally, we assessed the correlations of IL-27 levels with the clinical characteristics of MG. As a result, serum IL-27 levels were significantly higher in MG patients than those in the HCs. Meanwhile, significant reduction was detected after the IVIG treatment. IL-27 levels positively correlated with both MG activities of daily living and quantitative MG score. IL-27 may participate in the pathogenesis of MG and can be used as an early marker for the diagnosis and prognosis of MG. In addition, IL-27 can be used as a target for MG treatment through the regulation of specific immune signaling and maintaining immune homeostasis.

中文翻译：

---

重症肌无力患者的白细胞介素27水平

属于IL-12家族的白细胞介素27（IL-27）通过调节表达和叉头盒P3（FoxP3）的功能来影响T细胞（Tregs）的功能。在这项研究中，我们检测了59例重症肌无力（MG）和35例健康对照（HCs）中的IL-27血清水平。其中，32例MG患者接受了免疫球蛋白静脉注射（IVIG）注射（连续5天每天0.4 g / kg）。在治疗之前和之后收集IL-27水平，并进行比较研究。最后，我们评估了IL-27水平与MG临床特征的相关性。结果，MG患者的血清IL-27水平显着高于HC患者。同时，在IVIG治疗后发现明显减少。IL-27水平与日常生活中的MG活动和定量MG得分均呈正相关。IL-27可能参与了MG的发病机制，可以作为MG诊断和预后的早期标志物。另外，IL-27可以通过调节特异性免疫信号和维持免疫稳态来用作MG治疗的靶标。